SPRB Insider Trading
Insider Ownership Percentage: 6.90%
Insider Buying (Last 12 Months): $4,584.96
Insider Selling (Last 12 Months): $4,918.98
Spruce Biosciences Share Price & Price History
Current Price: $72.40
Price Change: ▲ Price Increase of +1.55 (2.19%)
As of 02/6/2026 05:00 PM ET
Spruce Biosciences Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/6/2025 | Parkman Healthcare Partners Ll | Major Shareholder | Buy | 256 | $17.91 | $4,584.96 | 1,307 |  |
| 10/6/2025 | Parkman Healthcare Partners Ll | Major Shareholder | Sell | 257 | $19.14 | $4,918.98 | 1,050 | |
| 3/20/2024 | Holdings A/S Novo | Major Shareholder | Sell | 4,799 | $54.75 | $262,745.25 | 40,200 | |
| 3/18/2024 | Holdings A/S Novo | Major Shareholder | Sell | 11,226 | $57.75 | $648,301.50 | 52,906 | |
| 3/14/2024 | Holdings A/S Novo | Major Shareholder | Sell | 25,497 | $66.75 | $1,701,924.75 | 64,133 | |
Spruce Biosciences Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/14/2025 | Cable Car Capital LP | 26,666 | $0.24M | 0.1% | N/A | 5.333% |  |
| 11/7/2025 | Carlyle Group Inc. | 2,896,518 | $24.77M | 0.6% | N/A | 579.304% | |
| 2/14/2025 | Boothbay Fund Management LLC | 288,800 | $0.12M | 0.0% | N/A | 0.699% | |
| 2/13/2025 | Renaissance Technologies LLC | 405,900 | $0.17M | 0.0% | -33.4% | 0.983% | |
| 8/16/2024 | Almitas Capital LLC | 396,506 | $0.21M | 0.1% | N/A | 0.964% | |
| 8/9/2024 | Renaissance Technologies LLC | 366,100 | $0.19M | 0.0% | +35.1% | 0.890% | |
| 8/6/2024 | Acadian Asset Management LLC | 1,367,997 | $0.71M | 0.0% | +270.9% | 3.324% | |
| 5/16/2024 | AWM Investment Company Inc. | 200,000 | $0.16M | 0.0% | N/A | 0.486% | |
| 5/10/2024 | Acadian Asset Management LLC | 368,831 | $0.29M | 0.0% | N/A | 0.896% | |
| 4/25/2024 | Rosalind Advisors Inc. | 1,508,419 | $1.19M | 1.1% | -4.9% | 3.666% | |
| 2/14/2024 | Superstring Capital Management LP | 118,814 | $0.35M | 0.2% | N/A | 0.292% | |
| 2/13/2024 | Armistice Capital LLC | 2,230,000 | $6.53M | 0.1% | -27.0% | 5.478% | |
| 2/12/2024 | AIGH Capital Management LLC | 2,123,863 | $6.22M | 2.5% | +75.4% | 5.217% | |
| 2/9/2024 | Worth Venture Partners LLC | 526,933 | $1.54M | 0.8% | +74.4% | 1.294% | |
| 11/15/2023 | Worth Venture Partners LLC | 302,074 | $0.68M | 0.4% | +8.8% | 0.742% | |
| 11/15/2023 | Armistice Capital LLC | 3,056,000 | $6.91M | 0.1% | -12.6% | 7.507% | |
| 11/13/2023 | AIGH Capital Management LLC | 1,211,000 | $2.74M | 1.3% | +9.0% | 2.975% | |
| 7/26/2023 | Privium Fund Management B.V. | 24,554 | $52K | 0.0% | N/A | 0.062% | |
| 5/15/2023 | AIGH Capital Management LLC | 1,104,000 | $2.37M | 0.9% | N/A | 2.778% | |
| 5/5/2023 | Carlyle Group Inc. | 2,896,518 | $6.40M | 0.2% | N/A | 7.287% | |
| 5/3/2023 | Privium Fund Management UK Ltd | 24,554 | $53K | 0.0% | -51.3% | 0.062% | |
| 5/1/2023 | Virtu Financial LLC | 13,722 | $30K | 0.0% | N/A | 0.035% | |
| 5/1/2023 | Marquette Asset Management LLC | 55,757 | $0.12M | 0.0% | -18.4% | 0.140% | |
| 4/27/2023 | RiverVest Venture Management LLC | 2,936,281 | $6.49M | 7.5% | +36.7% | 7.387% | |
| 2/13/2023 | BML Capital Management LLC | 221,830 | $0.24M | 0.2% | N/A | 0.942% | |
| 2/9/2023 | Privium Fund Management UK Ltd | 50,400 | $55K | 0.0% | N/A | 0.214% | |
| 1/12/2023 | Marquette Asset Management LLC | 68,357 | $75K | 0.0% | +6.7% | 0.290% | |
| 11/14/2022 | Ergoteles LLC | 23,032 | $32K | 0.0% | -45.0% | 0.098% | |
| 11/10/2022 | Abingworth LLP | 1,792,518 | $2.47M | 0.8% | N/A | 7.608% | |
| 10/18/2022 | Bailard Inc. | 21,166 | $29K | 0.0% | N/A | 0.090% | |
| 7/15/2022 | Marquette Asset Management LLC | 64,090 | $0.11M | 0.0% | +56.9% | 0.273% | |
| 2/10/2022 | Acadian Asset Management LLC | 71,756 | $0.32M | 0.0% | N/A | 0.306% | |
| 1/19/2022 | Marquette Asset Management LLC | 40,853 | $0.18M | 0.0% | N/A | 0.174% | |
| 11/16/2021 | Laurion Capital Management LP | 11,337 | $68K | 0.0% | -24.2% | 0.048% | |
| 11/15/2021 | Deerfield Management Company L.P. Series C | 2,200,000 | $13.22M | 0.3% | +7.5% | 9.411% | |
| 11/15/2021 | Rock Springs Capital Management LP | 1,617,601 | $9.72M | 0.2% | +0.8% | 6.919% | |
| 11/15/2021 | Caas Capital Management LP | 27,546 | $0.17M | 0.0% | -70.2% | 0.118% | |
| 11/12/2021 | Trexquant Investment LP | 11,998 | $72K | 0.0% | N/A | 0.051% | |
Data available starting January 2016
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Read More on Spruce Biosciences
Today's Range
Now: $72.40
52 Week Range
Now: $72.40
Volume
29,993 shs
Average Volume
24,614 shs
Market Capitalization
$77.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
3.52
Who are the company insiders with the largest holdings of Spruce Biosciences?
